Velvio GmbH
Research organisation
Velvio GmbH
Description
Velvio develops medicines to restore organ repair functions as treatment for Orphan Diseases in Neurodegeneration ā first of all Amyotrophic Lateral Sclerosis (ALS). Further, Velvio is innovating new opportunities in Idiopathic Pulmonary Fibrosis (IPF) and treatment concepts in Immune-Oncology, Liver and Brain Tumors. From our broad compound pipeline, we are ready to go āfirst in manā with ALS and we are about to finish preclinical drug development in IPF.
Velvio GmbH
Address
Am Biopark 11 93053 Regensburg | Germany
93053 Regensburg
93053 Regensburg
Contact
office@velvio.com
Description
Velvio develops medicines to restore organ repair functions as treatment for Orphan Diseases in Neurodegeneration ā first of all Amyotrophic Lateral Sclerosis (ALS). Further, Velvio is innovating new opportunities in Idiopathic Pulmonary Fibrosis (IPF) and treatment concepts in Immune-Oncology, Liver and Brain Tumors. From our broad compound pipeline, we are ready to go āfirst in manā with ALS and we are about to finish preclinical drug development in IPF.
Matchmaking
Connect with Velvio GmbH
This entity is yours?
Update informationPosition on the value chain
With the ultimate aim to create a European alliance for bioproduction in Europe, organisations have joined forces with COBIOE. Discover who are our associates.
Bio-resources and biobanking
- Cells, tissues and humanized xeno-organs
- Biosamples
- Viral, phage or bacterial specimen
Identification of biotherapies
- Target identification
- Target validation
- Screening
Drug design
- Drug assessment
- Drug engineering
- In vitro preclinical studies
Clinical validation
- Clinical trials
- In vivo preclinical validation
- Pre-industrial scale production
Production
- Upstream processes
- Downstream processes
- Quality control
Market access
- CE mark / market authorisation
- Payment / Reimbursement
- Care pathways